Literature DB >> 1600134

Renal structure and function in insulin-dependent diabetes mellitus and type I membranoproliferative glomerulonephritis in humans.

S M Mauer1, P Lane, M Hattori, P Fioretto, M W Steffes.   

Abstract

Renal pathological changes of diabetes include thickening of all renal extracellular basement membranes and the mesangial matrix and, to a lesser extent, mesangial cell expansion. Two renal lesions appear critical in diabetic nephropathy. Mesangial expansion out of proportion to the size of the glomerulus is related to proteinuria, hypertension, and declining GFR. Arteriolar hyalinosis is related to global glomerulosclerosis, and both are correlated with the clinical features of nephropathy. By the time renal dysfunction is clinically detectable, these lesions tend to be advanced. Interstitial volume may be increased in insulin-dependent diabetes mellitus, particularly in areas containing sclerotic glomeruli or marked tubular atrophy. Parallel findings were documented for type I membranoproliferative glomerulonephritis in which the increased mesangial volume fraction was related to decreased GFR, increased glomerular permeability to protein, and hypertension. As in diabetes, the cortical interstitial volume fraction is correlated with functional abnormalities in type I membranoproliferative glomerulonephritis. Thus, in both of these chronic glomerular disorders, mesangial expansion and interstitial expansion are associated with disordered renal function. Thus, it is not true that glomerular structural changes correlate poorly with glomerular function. Whether it is the glomerular or interstitial pathology or both that is causally responsible for the dysfunction requires further study.

Entities:  

Mesh:

Year:  1992        PMID: 1600134     DOI: 10.1681/ASN.V210s181

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  5 in total

1.  Proteomic identification and immunolocalization of increased renal calbindin-D28k expression in OVE26 diabetic mice.

Authors:  Visith Thongboonkerd; Shirong Zheng; Kenneth R McLeish; Paul N Epstein; Jon B Klein
Journal:  Rev Diabet Stud       Date:  2005-05-10

Review 2.  The role of sulodexide in the treatment of diabetic nephropathy.

Authors:  Ram Weiss; Robert Niecestro; Itamar Raz
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Hyperglycemia and renal mass ablation synergistically augment albuminuria in the diabetic subtotally nephrectomized rat: implications for modeling diabetic nephropathy.

Authors:  Li-Hao Chen; Bailey Stead; Suzanne L Advani; Noreen Yaqoob; Kerri Thai; M Golam Kabir; Darren A Yuen; Kim A Connelly; Richard E Gilbert; Andrew Advani
Journal:  Nephron Extra       Date:  2012-05-12

4.  Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy.

Authors:  Kei Fukami; Sho-Ichi Yamagishi; Melinda T Coughlan; Brooke E Harcourt; Phillip Kantharidis; Vicki Thallas-Bonke; Seiya Okuda; Mark E Cooper; Josephine M Forbes
Journal:  Diabetol Metab Syndr       Date:  2014-08-13       Impact factor: 3.320

5.  DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy.

Authors:  Yusuke Kaida; Kei Fukami; Takanori Matsui; Yuichiro Higashimoto; Yuri Nishino; Nana Obara; Yosuke Nakayama; Ryotaro Ando; Maki Toyonaga; Seiji Ueda; Masayoshi Takeuchi; Hiroyoshi Inoue; Seiya Okuda; Sho-ichi Yamagishi
Journal:  Diabetes       Date:  2013-04-29       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.